Mozobil 24 mg/1.2mL (Plerixafor INJECTION, SOLUTION) 24 mg/1.2mL

Mozobil 24 mg/1.2mL is a subcutaneous injection solution containing plerixafor, used to mobilize hematopoietic stem cells. This medication is typically administered under medical supervision for specific therapeutic purposes.

Strength

24 mg/1.2mL

Pack Size

1 VIAL, SINGLE-USE in 1 CARTON (0024-5862-01) / 1.2 mL in 1 VIAL, SINGLE-USE

Manufacturer / TM Owner

Sanofi-Aventis U.S. LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Mozobil is primarily used to mobilize hematopoietic stem cells into the bloodstream. This process is often part of preparatory treatments for certain medical procedures. Plerixafor, the active ingredient, works by stimulating the movement of these cells, which can be crucial for therapies requiring stem cell transplantation.

Side Effects

Common effects of Mozobil may include localized reactions at the injection site, such as redness or swelling. Some individuals might experience general discomfort or mild systemic reactions. It's important to monitor for any unusual symptoms and consult a healthcare provider if concerns arise.

Precautions & Warnings

Mozobil should be handled with care, ensuring proper storage and administration techniques. It is intended for single-use only and should not be shared between patients. Always follow the guidance of a healthcare professional regarding its use and potential risks.

Avoid Interactions

Mozobil may interact with other medications, particularly those that affect the immune system or blood cell production. It's essential to inform your healthcare provider about all current medications to avoid potential interactions. Alcohol and certain supplements might also influence its effects.

References

Frequently Asked Questions

Mozobil is used to mobilize hematopoietic stem cells into the bloodstream, often as part of preparatory treatments for certain medical procedures.

Mozobil is administered via subcutaneous injection, typically under medical supervision.

Common side effects may include localized reactions at the injection site, such as redness or swelling, and general discomfort.

Mozobil may interact with other medications, so it's important to consult a healthcare provider about all current medications.

Mozobil is typically used for specific, short-term purposes. Long-term use should be discussed with a healthcare provider.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.